Skip to content

Cytokinetics CYTK Income Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$105.82M+20.2%$88.04M+0.9%$87.21M+1.7%$85.74M+346%$19.22M+4.0%
$411.71M-0.7%$414.45M+2.7%$403.68M+3.8%$389.06M+9.3%$356.1M+4.9%
$284.27M+11.5%$254.89M+5.3%$242.08M+6.6%$227.18M+5.5%
$746.06M+6.5%$700.3M+6.1%$660.14M+4.3%$632.72M+8.2%$584.86M+5.4%
-$640.25M-4.6%-$612.26M-6.9%-$572.93M-4.7%-$546.98M+3.3%-$565.64M-5.5%
-605.1%+90.4pp-695.4%-38.5pp-656.9%-19.0pp-638%+2,305pp-2,943.3%-40.6pp
$51.23M+12.4%$45.58M+13.3%$40.24M+6.4%$37.82M-4.2%$39.47M+4.7%
$45.74M-5.5%$48.42M-6.8%$51.96M-11.6%$58.77M+2.5%$57.32M+11.2%
-$829.61M-5.7%-$784.96M-4.4%-$751.94M-24.0%-$606.31M+1.5%-$615.26M-4.4%
-784%+108pp-891.6%-29.4pp-862.2%-155pp-707.2%+2,494pp-3,201.5%-10.4pp
-$6.84-4.7%-$6.53-3.8%-$6.29-23.3%-$5.10+3.6%-$5.29-0.6%
-$629.04M-4.5%-$602.13M-6.9%-$563.29M-4.8%-$537.6M+3.3%-$556.14M-5.6%
-594.5%+89.5pp-683.9%-38.1pp-645.9%-18.9pp-627%+2,267pp-2,893.9%-42.7pp
-$640.25M-4.6%-$612.26M-6.9%-$572.93M-4.7%-$546.98M+3.3%-$565.64M-5.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Cytokinetics's revenue?
Cytokinetics (CYTK) generated $105.8M in revenue over the trailing twelve months, up 450.6% year over year.
Is Cytokinetics profitable?
Cytokinetics is not currently profitable: it reported a net loss of $829.6M over the trailing twelve months, a -784.0% net margin.
What is Cytokinetics's earnings per share?
Cytokinetics's diluted EPS over the trailing twelve months is $-6.84.
Where does Cytokinetics's income statement data come from?
Every line is extracted from Cytokinetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.